STAGE I October 2022 selection

The INCATE Selection Committee selected another 5 ventures for Stage I support in Q4 2022. The selected ventures are

  • KINZBIO – a start-up in Uruguay developing phages as disinfectant for ICUs
  • CCBIO – a UK start-up offering a platform to select novel endolysins
  • HIPS(Helmholtz Institute for Pharmaceutical Research Saarland – Chlorotonils against multidrug-resistant Gram-positive bacterial pathogens and Plasmodium spp
  • HZI (Helmholtz Centre for Infection Research) – Small molecule inhibitors of α-hemolysin for the treatment of S. aureus lung infections and
  • Justus-Liebeg University Giessen – Developing novel Darobactin analogues

Information on the other companies selected in previous stage I applications are on the portfolio page here.

INCATE
community
signup

Stay informed on events
and applications!

Go